Connect with us!
Like us!
Follow us!

Achieving unmet medical
needs and enhancing
consumer benefits.

We have worked on various drug delivery technology platforms including barrier membrane technology, matrix systems and osmotic systems. We have developed nine proprietary technologies for drug delivery and the two most notable among them are:

RubiERT®

Application area: Modified release

  • Combines non-swelling pH dependent and pH independent release retardants
  • Non-swelling nature of the dosage form can reduce plateau in the release profile and allows for complete release of the drug
  • Drug molecule experiences reduced diffusion path-length compared to swelling systems
  • Due to non-swelling nature a more predictable GI transit time is expected
  • Candidate molecules: Tramadol, Ropinirole

Contact us: Email us at bd@rubicon.co.in if your product needs a unique release profile.

RubiReten®

A gastro-retentive system for drugs with poor solubility and a limited window of absorption. As on March 31, 2024, our proprietary technologies are backed by 10 patents in various countries including India and the US, which we can leverage for the development of value-added specialty products.

Candidate molecules: Valsartan, Pregabalin

Contact us: Email us at bd@rubicon.co.in if your product requires absorption in the upper part of the gastrointestinal tract (GIT).

RubiSRL®

For the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and

Candidate molecules: Dextromethorphan Polistirex, Methylphenidate

Contact us: Email us at bd@rubicon.co.in if your liquid product requires a controlled release profile.

RubiDT®

Application area: Instant dispersions with taste masking

  • Employs high viscosity polymer
  • Reduces the movement of particles, thereby ensuring uniformity of the drug content
  • Unique feature of the technology is the rapid disintegration with retarded sedimentation rate
  • Reduction in variability of response

Candidate molecules: Diclofenac, Linezolid, Azithromycin, Calcium Citrate, Calcium Orotate, Sildenafil Citrate

Contact us: Email us at bd@rubicon.co.in if your product needs a taste-masked solution in an alternate dosage format or you are pursuing a product for populations with dysphagia (pediatric and geriatric).

Apart from the above technologies, Rubicon Research’s experience involves working with Barrier Membrane Technology, Matrix Systems, and Osmotic Systems. Reach out to us to have a conversation about your drug development needs. We work from the first principles of science to develop custom-made solutions because we understand that every problem is unique.

By leveraging our R&D infrastructure and ecosystem, we can take your product to clinic and to the market at the earliest.